Medtronic’s clinical trial flop may signal the end for renal denervation in treating hypertension, according to a co-primary principal investigator involved with Medtronic’s SYMPLICITY HTN-3 trial. The future of renal denervation in treatment of hypertension is shaky at best, according to one of the principal investigators involved with Medtronic’s disappointing clinical trial. Despite continued optimism from some of medtech’s biggest players, the fact that renal denervation failed in Medtronic’s highly anticipated SYMPLICITY HTN-3 clinical trial to meet its efficacy endpoint may signal the end of the technology, the anonymous investigator told Leerink Swann analysts.
Help employers find you! Check out all the jobs and post your resume.
